[CAS NO. 36341-25-0] YL-109

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [36341-25-0]

Catalog

HY-18619

Brand

MCE

CAS

36341-25-0

DESCRIPTION [36341-25-0]

Overview

MDL	MFCD00030231
Molecular Weight	257.31
Molecular Formula	C14H11NO2S
SMILES	OC1=CC=C(C2=NC3=CC=CC=C3S2)C=C1OC

For research use only. We do not sell to patients.

Summary

YL-109 is an antitumor agent that can induce carboxyl terminus of Hsp70-interacting protein (CHIP) expression through aryl hydrocarbon receptor (AhR) signaling. YL-109 has ability to inhibit breast cancer cell growth and invasiveness ^[1] .

In Vitro

YL-109 (0.001-10 μM; 96 h or 24 h) inhibits cell proliferation, motility, and invasiveness in breast cancer cells ^[1] .
YL-109 (1 μM) increases both CHIP mRNA and protein levels in MDA-MB-231 cells ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay ^[1]

Cell Line:	MCF-7 and MDA-MB-231 cells
Concentration:	0.001, 0.01, 0.1, 1, 10 μM
Incubation Time:	96 hours
Result:	Strongly inhibited cell proliferation of MCF-7 and MDA-MB-231 cells in a dose-dependent manner (IC ₅₀ =85.8 nM and 4.02 μM, respectively).

In Vivo

YL-109 (15 mg/kg; s.c. for every 2 d) inhibits both tumor growth and cancer metastasis of breast cancer cells in vivo ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/cAjcl-nu/nu female mice (4-5 weeks) inoculated with MCF-7 or MDA-MB-231 cells ^[1]
Dosage:	15 mg/kg
Administration:	S.c. every 2 days for 63 days
Result:	Suppressed tumor growth in mice injected with MCF-7 and MDA-MB-231 cells.

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 388.64 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.8864 mL	19.4318 mL	38.8636 mL
5 mM	0.7773 mL	3.8864 mL	7.7727 mL
10 mM	0.3886 mL	1.9432 mL	3.8864 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 3 mg/mL (11.66 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: 3 mg/mL (11.66 mM); Clear solution; Need ultrasonic
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 3 mg/mL (11.66 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Hiyoshi H, et al. 2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses tumor progression and metastatic potential of breast cancer cells by inducing ubiquitin ligase CHIP. Sci Rep. 2014 Nov 18;4:7095.